Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Common Equity: 2017-2018

Historic Common Equity for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to $34.9 million.

  • Astria Therapeutics' Common Equity fell 5.54% to $38.3 million in Q3 2019 from the same period last year, while for Sep 2019 it was $38.3 million, marking a year-over-year decrease of 5.54%. This contributed to the annual value of $34.9 million for FY2018, which is 196.32% up from last year.
  • As of FY2018, Astria Therapeutics' Common Equity stood at $34.9 million, which was up 196.32% from $11.8 million recorded in FY2017.
  • Astria Therapeutics' Common Equity's 5-year high stood at $34.9 million during FY2018, with a 5-year trough of $11.8 million in FY2017.
  • For the 2-year period, Astria Therapeutics' Common Equity averaged around $23.4 million, with its median value being $23.4 million (2017).
  • Data for Astria Therapeutics' Common Equity shows a peak YoY skyrocketed of 196.32% (in 2018) over the last 5 years.
  • Over the past 2 years, Astria Therapeutics' Common Equity (Yearly) stood at $11.8 million in 2017, then soared by 196.32% to $34.9 million in 2018.